Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 5/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28140302 | 0.98 | CA2 (0.50) | NLRP3TSHRCA2FAAHCES1 | |
| SCHEMBL28141077 | 0.98 | CA2 (0.50) | NLRP3TSHRCA2FAAHCES1 | |
| SCHEMBL28140282 | 0.98 | CA2 (0.50) | NLRP3TSHRCA2FAAHCES1 | |
| SCHEMBL25289503 | 0.93 | NLRP3 (0.50) | NLRP3TSHRCA2FAAHCES1 | |
| SCHEMBL16255357 | 0.84 | NLRP3 (0.54) | NLRP3TSHR | |
| SCHEMBL1164349 | 0.84 | NLRP3 (0.52) | NLRP3TSHR | |
| SCHEMBL9941 | 0.81 | CA2 (0.64) | TSHRCA2FAAHCES1CES2 | |
| SCHEMBL5663638 | 0.81 | NLRP3 (0.60) | NLRP3TSHR | |
| SCHEMBL4073173 | 0.80 | CA2 (0.48) | NLRP3TSHRCA2FAAHCES1 | |
| Cyanide SCHEMBL28371958 | 0.79 | CA2 (0.56) | CA2FAAHCES1CES2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015081188-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-(ARYLSULFONYL)ALKYLNITRILE | OLATEC INDUSTRIES LLC (US) | 2015-06-04 | — | — | WO | disclosed |
| CN-104363902-A | Pharmaceutical composition for treating inflammation and pain | OLATEC IND LLC | 2015-02-18 | — | — | CN | disclosed |
| EP-1807393-B1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1807393-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | Merck Sharp & Dohme Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| EP-1786768-A1 | ARYLSULPHONYLSTILBENE DERIVATIVES FOR TREATMENT OF INSOMNIA AND RELATED CONDITIONS | Merck Sharp & Dohme Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021806-A1 | ARYLSULPHONYLSTILBENE DERIVATIVES FOR TREATMENT OF INSOMNIA AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | NLRP3 4464/4885TSHR 283/4885CA2 4755/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | NLRP3 4464/4885TSHR 283/4885CA2 4755/4885 |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | HTR2A, HTR2B, HTR1A | NLRP3 4464/4885TSHR 283/4885CA2 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.